215 related articles for article (PubMed ID: 25139999)
1. Axl kinase as a key target for oncology: focus on small molecule inhibitors.
Feneyrolles C; Spenlinhauer A; Guiet L; Fauvel B; Daydé-Cazals B; Warnault P; Chevé G; Yasri A
Mol Cancer Ther; 2014 Sep; 13(9):2141-8. PubMed ID: 25139999
[TBL] [Abstract][Full Text] [Related]
2. Targeting Axl and Mer kinases in cancer.
Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
[TBL] [Abstract][Full Text] [Related]
3. Axl inhibitors as novel cancer therapeutic agents.
Shen Y; Chen X; He J; Liao D; Zu X
Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
[TBL] [Abstract][Full Text] [Related]
4. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
5. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I; Conciatori F; Bazzichetto C; Bria E; Carbognin L; Malaguti P; Ferretti G; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182542
[TBL] [Abstract][Full Text] [Related]
6. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
7. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
Schoumacher M; Burbridge M
Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
9. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
Linger RM; Keating AK; Earp HS; Graham DK
Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma.
Li Y; Wang X; Bi S; Zhao K; Yu C
Biochem Biophys Res Commun; 2015 Feb; 457(3):461-6. PubMed ID: 25596315
[TBL] [Abstract][Full Text] [Related]
12. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
13. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
14. AXL receptor as an emerging molecular target in colorectal cancer.
De Rosa L; Di Stasi R; Fusco V; D'Andrea LD
Drug Discov Today; 2024 Jun; 29(6):104005. PubMed ID: 38685399
[TBL] [Abstract][Full Text] [Related]
15. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
Kim NY; Suh YA; Kim S; Lee C
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32219334
[TBL] [Abstract][Full Text] [Related]
16. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.
Linger RM; Keating AK; Earp HS; Graham DK
Adv Cancer Res; 2008; 100():35-83. PubMed ID: 18620092
[TBL] [Abstract][Full Text] [Related]
17. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
19. AXL kinase as a novel target for cancer therapy.
Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
[TBL] [Abstract][Full Text] [Related]
20. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
[Next] [New Search]
